INDIA’s Serum Institute has sought approval for emergency use of AstraZeneca Plc’s Covid-19 vaccine in the country, its chief executive officer said on Monday(7).
Serum Institute is the world’s largest vaccine producer by volume.
The UK pharmaceutical giant is chasing rivals Pfizer Inc and Moderna Inc with a vaccine that has less stringent storage requirements and is expected to be easier to distribute and faster to scale up in production than others.
But it is also facing queries from scientists over its trial data, which showed a 1.5 dose regimen delivered more than 90 per cent efficacy and a full two-dose regimen just 62 per cent, both administered over two stages.
Serum Institute, seeking to deliver supplies for a domestic coronavirus outbreak that is the world’s second biggest, has said an emergency use approval could preface a full rollout by February or March.
Serum Institute CEO Adar Poonawalla tweeted that the move to apply for emergency use “will save countless lives,” but did not give any other details.
AstraZeneca’s vaccine, called “Covishield” by Serum Institute, can be stored at two to eight degrees Celsius and distributed more easily in India, which lacks cold chain capabilities that the vaccine developed by Pfizer requires.
Poonawalla has said the company will first focus on supplying the vaccine in India before distributing it to other countries, pricing it at Rs 1,000 per dose ($13.50) for private markets.
Governments signing large supply deals will likely buy it at lower prices. In Europe, AstraZeneca has pledged to supply 300 million doses of the vaccine for around £685 million.
Over the weekend, a top Indian government health adviser said in a TV interview that Pfizer had applied for an emergency use authorization for its vaccine in the country.
An effective vaccine is increasingly being seen critical by governments as the only way to end a pandemic that has taken more than a million lives around the world.
Britain and some other nations have pressed on with plans to roll out the AstraZeneca vaccine, while the Philippines and Thailand secured millions of doses, giving the shot a vote of confidence after experts raised questions about trial data.
